Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2005 1
2010 1
2011 1
2012 1
2013 4
2015 3
2016 3
2018 3
2019 2
2020 5
2021 5
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators. Sullivan KM, et al. Among authors: keyes elstein l. N Engl J Med. 2018 Jan 4;378(1):35-47. doi: 10.1056/nejmoa1703327. N Engl J Med. 2018. PMID: 29298160 Free PMC article. Clinical Trial.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Herold KC, et al. Among authors: keyes elstein l. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8. Diabetes. 2013. PMID: 23835333 Free PMC article. Clinical Trial.
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.
Chakravarty EF, Utset T, Kamen DL, Contreras G, McCune WJ, Aranow C, Kalunian K, Massarotti E, Clowse MEB, Rovin BH, Lim SS, Majithia V, Dall'Era M, Looney RJ, Erkan D, Saxena A, Olsen NJ, Ko K, Guthridge JM, Goldmuntz E, Springer J, D'Aveta C, Keyes-Elstein L, Barry B, Pinckney A, McNamara J, James JA. Chakravarty EF, et al. Among authors: keyes elstein l. Lancet Rheumatol. 2024 Mar;6(3):e168-e177. doi: 10.1016/S2665-9913(23)00320-X. Epub 2024 Jan 29. Lancet Rheumatol. 2024. PMID: 38301682 Clinical Trial.
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.
Ayoglu B, Donato M, Furst DE, Crofford LJ, Goldmuntz E, Keyes-Elstein L, James J, Macwana S, Mayes MD, McSweeney P, Nash RA, Sullivan KM, Welch B, Pinckney A, Mao R, Chung L, Khatri P, Utz PJ. Ayoglu B, et al. Among authors: keyes elstein l. Ann Rheum Dis. 2023 May;82(5):670-680. doi: 10.1136/ard-2021-221926. Epub 2023 Jan 18. Ann Rheum Dis. 2023. PMID: 36653124 Free PMC article.
Cross-trial comparisons in reviews: proceed with caution.
Sullivan KM, Keyes-Elstein L. Sullivan KM, et al. Among authors: keyes elstein l. Nat Rev Rheumatol. 2020 Dec;16(12):663-664. doi: 10.1038/s41584-020-0492-3. Nat Rev Rheumatol. 2020. PMID: 32807928 No abstract available.
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.
Wareing N, Wang X, Keyes-Elstein L, Goldmuntz EA, Lyons MA, McSweeney P, Furst DE, Nash RA, Crofford LJ, Welch B, Pinckney A, Mayes MD, Sullivan KM, Assassi S. Wareing N, et al. Among authors: keyes elstein l. Arthritis Rheumatol. 2024 Mar 18. doi: 10.1002/art.42847. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 38497141
Unique Sjögren's syndrome patient subsets defined by molecular features.
James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. James JA, et al. Among authors: keyes elstein l. Rheumatology (Oxford). 2020 Apr 1;59(4):860-868. doi: 10.1093/rheumatology/kez335. Rheumatology (Oxford). 2020. PMID: 31497844 Free PMC article.
Machine learning predicts stem cell transplant response in severe scleroderma.
Franks JM, Martyanov V, Wang Y, Wood TA, Pinckney A, Crofford LJ, Keyes-Elstein L, Furst DE, Goldmuntz E, Mayes MD, McSweeney P, Nash RA, Sullivan KM, Whitfield ML. Franks JM, et al. Among authors: keyes elstein l. Ann Rheum Dis. 2020 Dec;79(12):1608-1615. doi: 10.1136/annrheumdis-2020-217033. Epub 2020 Sep 15. Ann Rheum Dis. 2020. PMID: 32933919 Free PMC article.
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S; ITN058AI EXTEND Study Team. Greenbaum CJ, et al. Among authors: keyes elstein l. JCI Insight. 2021 Nov 8;6(21):e150074. doi: 10.1172/jci.insight.150074. JCI Insight. 2021. PMID: 34747368 Free PMC article. Clinical Trial.
35 results